SCHEMBL5597238

SCHEMBL5597238

Cn1c(N)c(NC(=O)c2c[nH]nc2Cc2cccc(C(F)(F)F)c2)c(=O)n(CC2CC2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.44
ADORA2B P29275 3/20 0.44
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
CRHR1 P34998 2/20 0.40
NR3C1 P04150 2/20 0.38
PDE5A O76074 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5059236 0.91 ADORA2A (0.42) ADORA3ADORA2BADORA2AADORA1SMN1; SMN2
SCHEMBL5054303 0.82 ADORA2B (0.42) ADORA3ADORA2BADORA2AADORA1SMN1; SMN2
SCHEMBL5597387 0.80 ADORA2A (0.39) ADORA3ADORA2BADORA2AADORA1MAPT
SCHEMBL1546006 0.79 ADORA2B (0.57) ADORA3ADORA2BADORA2AADORA1
SCHEMBL6014101 0.71 ADORA2B (0.40) ADORA3ADORA2BADORA2AADORA1SMN1; SMN2
SCHEMBL1546710 0.71 ADORA2B (0.57) ADORA3ADORA2BADORA2AADORA1CRHR1
SCHEMBL1546111 0.68 ADORA2A (0.55) ADORA3ADORA2BADORA2AADORA1
SCHEMBL1697133 0.68 NR4A2 (0.48) MAPTCYP3A4ALDH1A1MEN1KMT2A
SCHEMBL5509419 0.68 ADORA3 (0.44) ADORA3ADORA2BADORA2AADORA1SMN1; SMN2
SCHEMBL1546107 0.67 ADORA2B (0.54) ADORA3ADORA2BADORA2AADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799221-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-06-27 EP disclosed
WO-2006044610-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC (US) 2006-04-27 WO disclosed